Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb study of milciclib in combination with the standard of care treatment sorafenib in patients with hepatocellular carcinoma

Trial Profile

Phase IIb study of milciclib in combination with the standard of care treatment sorafenib in patients with hepatocellular carcinoma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milciclib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2019 According to a Tiziana Life Sciences media release, the company Expects to initiate a Phase 2b trial (TZLS (201)-125a-011) dosing Milciclib in combination with Sorafenib in patients with HCC in 2019.
    • 14 Dec 2017 Planned initiation date changed to 1 Apr 2018.
    • 11 Dec 2017 According to a Tiziana Life Sciences media release, this trial is expected to begin in in Q2, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top